Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTD versus TD for previously untreated symptomatic multiple myeloma eligible for double autologous transplantation
2005-003723-39Phase 3Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Dec 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, thalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Probability of response after primary induction therapy. Started Dec 2008; status: completed.
02
Drugs
bortezomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-003723-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003723-39.